On March 21, China Meheco Group Co.Ltd(600056) again raised the limit, and gained 11 limit boards in the past 14 trading days, with a cumulative increase of 230%.
Analysts believe that its continuous limit is related to the commercial operation of Pfizer covid-19 drugs. On the 21st, China Meheco Group Co.Ltd(600056) again issued a risk warning announcement, saying that the cooperation with Pfizer had no significant impact on the company’s recent operating performance.
In March 9th, China Meheco Group Co.Ltd(600056) said it would be responsible for the commercial operation of Pfizer COVID-19 virus Paxlovid in Chinese mainland market.
